Treatment of actinic cheilitis with the Er:YAG laser - 24/04/13
, Craig L. James, FRCPA b, Patrick C. Walker, FACD c, Shyamala C. Huilgol, FACD d
Correspondence to: Paul Armenores, Flinders Medical Centre, Flinders Drive, Bedford Park, South Australia, 5042, Australia.Abstract |
Background |
Actinic cheilitis is a common condition with the potential to develop into squamous cell carcinoma. Current treatments have varying cure rates and complications. The role of the erbium:yttrium-aluminum-garnet (Er:YAG) laser in the treatment of actinic cheilitis has not been widely published, despite offering theoretical advantages over current treatment modalities.
Objective |
To evaluate the outcome of a series of patients treated with the Er:YAG laser for actinic cheilitis.
Methods |
This was a retrospective, interventional, nonrandomized, sequential case series set in a tertiary referral, dermatologic surgery unit. Ninety-nine consecutive patients with actinic cheilitis treated with the Er:YAG laser between January 2001 and June 2008 underwent a case note review, of which 77 went on to a structured telephone interview. The main outcome measures were a subjective improvement in lip symptoms related to actinic cheilitis and objective improvement in the lips at routine follow-up.
Results |
Mean time to interview follow-up was 65.7 months. Of those interviewed, 92.2% believed there had been an improvement in the cosmetic appearance of their lips; one hundred percent believed the function of their lips had improved or remained unchanged; and 84.8% remained completely disease free at the time of follow-up. The majority of patients (93.5%) were satisfied with the laser treatment. Scarring as a direct result of the laser occurred in 5.1% of patients.
Limitations |
Retrospective nature of data collection; inability to interview all patients who underwent treatment.
Conclusion |
The Er:YAG laser is a successful modality for the treatment of actinic cheilitis with good functional and cosmetic results and only a small risk of long-term scarring. It should be considered as a first-line treatment for the disease.
Le texte complet de cet article est disponible en PDF.Plan
| Funding sources: None. |
|
| Conflicts of interest: None declared. |
|
| Reprints not available from the authors. |
Vol 63 - N° 4
P. 642-646 - octobre 2010 Retour au numéro
Article précédent
- Revised nomenclature and classification of inherited ichthyoses: Results of the First Ichthyosis Consensus Conference in Sorèze 2009
- Vinzenz Oji, Gianluca Tadini, Masashi Akiyama, Claudine Blanchet Bardon, Christine Bodemer, Emmanuelle Bourrat, Philippe Coudiere, John J. DiGiovanna, Peter Elias, Judith Fischer, Philip Fleckman, Michal Gina, John Harper, Takashi Hashimoto, Ingrid Hausser, Hans Christian Hennies, Daniel Hohl, Alain Hovnanian, Akemi Ishida-Yamamoto, Witold K. Jacyk, Sancy Leachman, Irene Leigh, Juliette Mazereeuw-Hautier, Leonard Milstone, Fanny Morice-Picard, Amy S. Paller, Gabriele Richard, Matthias Schmuth, Hiroshi Shimizu, Eli Sprecher, Maurice Van Steensel, Alain Taïeb, Jorge R. Toro, Pierre Vabres, Anders Vahlquist, Mary Williams, Heiko Traupe
- Influence of evaluation of clinical pictures on the histopathologic diagnosis of inflammatory skin disorders
- Lorenzo Cerroni, Zsolt Argenyi, Rino Cerio, Fabio Facchetti, Harald Kittler, Heinz Kutzner, Luis Requena, Omar P. Sangueza, Bruce Smoller, Janine Wechsler, Helmut Kerl
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?